Last reviewed · How we verify
Herombopag
Herombopag is a Small molecule drug developed by Yin Jie. It is currently in Phase 3 development. Also known as: Cyclosporine A, Platelet receptor agonists.
Herombopag is being studied in clinical trials for the treatment of Aplastic Anemia, Severe Aplastic Anemia, Immune Thrombocytopenia, and conditions related to drug therapy. It is being used in combination with immunosuppressive therapies such as cyclophosphamide and cyclosporine (CsA) in these trials.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Herombopag |
|---|---|
| Also known as | Cyclosporine A, Platelet receptor agonists |
| Sponsor | Yin Jie |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Herombopag Treated T-DM1 Induced Platelet Reduction (PHASE2)
- A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma (PHASE2)
- Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 Study (PHASE2)
- The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery (PHASE3)
- Primary Prevention of Thrombocytopenia Associated With T-DM1 Therapy in HER2 Positive Breast Cancer With Herombopag (NA)
- Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia (PHASE2)
- A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP (PHASE2)
- Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Herombopag CI brief — competitive landscape report
- Herombopag updates RSS · CI watch RSS
- Yin Jie portfolio CI
Frequently asked questions about Herombopag
What is Herombopag?
Who makes Herombopag?
Is Herombopag also known as anything else?
What development phase is Herombopag in?
Related
- Manufacturer: Yin Jie — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Cyclosporine A, Platelet receptor agonists
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing